CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Bicalutamide 150 Mg Oral TabletWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2698 Woebot Substance Use Disorder Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D000437 Alcoholism NIH 0.58
D019966 Substance-Related Disorders NIH 0.38
D004194 Disease NIH 0.18

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Phase II Trial to Promote Recovery From COVID-19 With Endocrine Therapy

Patients with COVID-19 requiring inpatient hospitalization will be randomized to treatment with standard of care or standard of care + bicalutamide. This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19.

NCT04374279 COVID-19 SARS-CoV 2 Drug: Bicalutamide 150 Mg Oral Tablet

Primary Outcomes

Description: Percentage of participants who are discharged from the hospital or if they have had at least a 2-point improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement. The WHO clinical improvement scale has a score range of 0-8 where, 0= uninfected, 1= ambulatory with no limitation of activities; 2= ambulatory with limitations to activities; 3= hospitalized, mild disease, with no oxygen therapy; 4= hospitalized, mild disease, with oxygen by mask or nasal prongs; 5= hospitalized, severe disease, with non-invasive ventilation or high-flow oxygen; 6= hospitalized, severe disease, with intubation and mechanical ventilation; 7= hospitalized, severe disease, with ventilation and additional organ support (pressors, dialysis, ECMO); 8= death

Measure: Percentage of participants who have clinical improvement at day 7 after randomization

Time: up to 7 days

Secondary Outcomes

Description: Number of participants deceased for any cause

Measure: All-cause mortality

Time: 28 days

Description: Number of calendar days in the hospital

Measure: Duration of hospitalization

Time: up to 60 days

Measure: Percentage of patients needing upgrade to the intermediate care unit (IMC)

Time: up to 60 days

Description: Number of calendar days in IMC

Measure: Duration of IMC stay

Time: up to 60 days

Measure: Percentage of patients needing upgrade to the intensive care unit (ICU)

Time: up to 60 days

Description: Number of calendar days in ICU

Measure: Duration of ICU stay

Time: up to 60 days

Measure: Number of participants requiring mechanical ventilation

Time: up to 60 days

Description: Number of calendar days requiring mechanical ventilation

Measure: Duration of mechanical ventilation

Time: up to 60 days

Description: Number of participants who are COVID-19 positive, experiencing adverse events as defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Measure: Number of participants experiencing adverse events

Time: up to 60 days

No related HPO nodes (Using clinical trials)